His primary scientific interests are in Biochemistry, Antibody, Immunology, In vivo and Molecular biology. In general Biochemistry study, his work on Peptide, Phage display and Serum albumin often relates to the realm of Conjugate, thereby connecting several areas of interest. His Antibody research includes elements of Peptide library, Pharmacology and Antigen.
His study in Immunology is interdisciplinary in nature, drawing from both Transferrin receptor, Receptor and Blood–brain barrier. His study looks at the relationship between In vivo and topics such as Antibody-drug conjugate, which overlap with Lymphoma and Chronic lymphocytic leukemia. His biological study deals with issues like Semaphorin, which deal with fields such as Blocking antibody.
His primary areas of investigation include Antibody, Biochemistry, Immunology, Molecular biology and Cancer research. As part of one scientific family, he deals mainly with the area of Antibody, narrowing it down to issues related to the Apoptosis, and often Nucleic acid. His study in Biochemistry focuses on Kallikrein, Peptide, Serine protease, Amino acid and Plasmin.
His research on Immunology focuses in particular on Immune system. His research in Molecular biology intersects with topics in Transferrin receptor and Receptor. In his study, Antibody-drug conjugate is strongly linked to In vivo, which falls under the umbrella field of Cancer research.
Mark S. Dennis mainly investigates Antibody, Biochemistry, Transferrin receptor, Cell biology and Blood–brain barrier. His work in the fields of Antibody, such as Immunoconjugate, intersects with other areas such as Linker. His Biochemistry study integrates concerns from other disciplines, such as Avidity and CD79B.
His studies deal with areas such as Penetrant, Knockout mouse and In vivo as well as Cell biology. His In vivo study incorporates themes from Cytokine, Toxicity and Therapeutic index. Mark S. Dennis works mostly in the field of Central nervous system, limiting it down to topics relating to Enzyme and, in certain cases, Pharmacology.
Mark S. Dennis spends much of his time researching Antibody, T cell, Transferrin receptor, Blood–brain barrier and In vivo. He is studying Monoclonal, which is a component of Antibody. The T cell study combines topics in areas such as Cytokine, Toxicity, Therapeutic index and Immunotherapy.
His work deals with themes such as Neuroinflammation, Central nervous system, Microglia and Cell biology, which intersect with Transferrin receptor. The various areas that Mark S. Dennis examines in his Blood–brain barrier study include Cell, Transferrin, Binding site and Immunoglobulin G. His In vivo study frequently draws connections to adjacent fields such as Pharmacology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
Jagath R Junutula;Helga Raab;Suzanna Clark;Sunil Bhakta.
Nature Biotechnology (2008)
Albumin Binding as a General Strategy for Improving the Pharmacokinetics of Proteins
Mark S. Dennis;Min Zhang;Y. Gloria Meng;Miryam Kadkhodayan.
Journal of Biological Chemistry (2002)
High-affinity human antibodies from phage-displayed synthetic Fab libraries with a single framework scaffold.
Chingwei V Lee;Wei-Ching Liang;Mark S Dennis;Charles Eigenbrot.
Journal of Molecular Biology (2004)
Boosting Brain Uptake of a Therapeutic Antibody by Reducing Its Affinity for a Transcytosis Target
Y. Joy Yu;Yin Zhang;Margaret Kenrick;Kwame Hoyte.
Science Translational Medicine (2011)
Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
Mark S. Dennis;Wei-Ching Liang;Yan Wu.
Platelet glycoprotein IIb-IIIa protein antagonists from snake venoms: evidence for a family of platelet-aggregation inhibitors.
Mark S. Dennis;William J. Henzel;Robert M. Pitti;Michael T. Lipari.
Proceedings of the National Academy of Sciences of the United States of America (1990)
Solution structure of kistrin, a potent platelet aggregation inhibitor and GP IIb-IIIa antagonist
Marc Adler;Robert A. Lazarus;Mark S. Dennis;Gerhard Wagner.
Imaging Tumors with an Albumin-Binding Fab, a Novel Tumor-Targeting Agent
Mark S. Dennis;Hongkui Jin;Debra Dugger;Renhui Yang.
Cancer Research (2007)
Rubber elongation factor from Hevea brasiliensis. Identification, characterization, and role in rubber biosynthesis.
M S Dennis;D R Light.
Journal of Biological Chemistry (1989)
Methods and compositions for prolonging elimination half-times of bioactive compounds
Warren L. Delano;Mark S. Dennis;Henry B. Lowman.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: